Recondo Gonzalo, Recondo Gonzalo, Galanternik Fernando, Greco Martín, de la Vega Máximo, Valsecchi Matías E
5170 U.S. Route 60 East, Huntington, WV 25705, USA.
Rev Recent Clin Trials. 2016;11(2):87-92. doi: 10.2174/1574887111666160330121349.
Lung cancer is a major public health problem worldwide and the leading cause of cancerrelated mortality in developed countries. Significant advances have been made especially with the discovery of targeted agents. However, only a small proportion of patients carry activating mutations; until recently conventional chemotherapy and angiogenesis inhibitors were the preferred treatment for the vast majority of patients. Now, the successful experience of anti-PD-1 agents may have opened the door to a novel and previously unexplored dimension in the treatment of lung cancer: immunotherapy. In this mini-review we will discuss the current applications and future consequences related this topic, paying special attention to the clinical studies that constitute the scientific evidence to supports its use.
肺癌是全球主要的公共卫生问题，也是发达国家癌症相关死亡的主要原因。尤其是随着靶向药物的发现，已经取得了重大进展。然而，只有一小部分患者携带激活突变；直到最近，传统化疗和血管生成抑制剂仍是绝大多数患者的首选治疗方法。现在，抗PD-1药物的成功经验可能为肺癌治疗开启了一个全新的、以前未被探索的维度：免疫疗法。在这篇小型综述中，我们将讨论与该主题相关的当前应用和未来影响，特别关注构成支持其使用的科学证据的临床研究。
